期刊文献+

米氮平致高泌乳素血症 被引量:2

Hyperprolactinemia induced by mirtazapine
下载PDF
导出
摘要 1例49岁女性患者,因"发作性头痛、头晕10年伴左肾上腺占位2个月"入院,诊断为左肾上腺无功能瘤可能性大。既往焦虑症病史4年,2019年4月20日给予米氮平片(15 mg·d^-1),劳拉西泮片(0.25 mg·d^-1),并间断口服坦度螺酮胶囊治疗。7月9日入院后体格检查发现双乳触发性溢乳,查血清泌乳素>200μg·L^-1,颅脑磁共振(MRI)未见异常,甲状腺功能无减退,其余检查未见异常。排除原发疾病及其他药物因素后,考虑高泌乳素血症与米氮平相关性大。后续对患者进行随访,米氮平减量为10 mg·d^-1,溢乳症状消失,未复查血清泌乳素情况。 One 49-year-old female patient was admitted to the hospital due to paroxysmal headache and dizziness for ten years accompanied with an occupation in left adrenal gland for two months.The high possibility of nonfunctional tumor in left adrenal gland was considered.She had a 4 years history of anxiety disorder and had been treated with mirtazapine tablets(15 mg·d^-1),lorazepam tablets(0.25 mg·d^-1)and intermittent tandospirone capsules since April 20th,2019.After admission on July 9th,triggered galactorrhea in bilateral nipples was found after physical examination.The level of serum prolactin was more than 200μg·L^-1.There were no abnormal findings in craniocerebral magnetic resonance imaging(MRI),thyroid function and other examinations.Hyperprolactinemia caused by mirtazapine was considered after excluding hyperprolactinemia associated with primary diseases and other drugs.Follow-up showed that galactorrhea was disappeared after the dose of mirtazapine was reduced to 10 mg·d-1 and the serum prolactin was not detected again.
作者 章开 汤智慧 ZHANG Kai;TANG Zhi-hui(Department of Pharmacy,Medical Supplies Center of Chinese PLA General Hospital,Beijing 100853,China;Department of Pharmacy,Tumor Hospital ofJiangxi Province,Nanchang 330029,China)
出处 《中国药物应用与监测》 CAS 2020年第6期425-427,共3页 Chinese Journal of Drug Application and Monitoring
关键词 米氮平 高泌乳素血症 溢乳 药品不良反应 Mirtazapine Hyperprolactinemia Galactorrhea Adverse drug reaction
  • 相关文献

参考文献6

二级参考文献19

  • 1贺又娥,张以文.子宫内膜异位症患者泌乳素分泌功能及其与黄体功能不足和不...[J].中华妇产科杂志,1993,28(1):14-17. 被引量:13
  • 2Schmutz JL, Barbaud A, Trechot P. Mirtazapin and gynecomastiagalactorrhea[ I ]. Ann Dermatol Yenereol, 2005, 132 (2) : 195.
  • 3Lynch A, Madjlessi A. Gynecomastia-galactorrhea during treatment with mirtazapine[ J]. Presse Med, 2004, 33 (7) :458.
  • 4Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 201 l, 96(2):273-288. DOI: 10.1210@.2010-1692.
  • 5Schulz KD, Geiger W, del Pozo E, et al. Pattern of sexual steroids, prolaetin, and gonadotropie hormones duringprolactin inhibition in normally cycling women[J]. Am J Obstet Gynecol, 1978, 132(5):561-566.
  • 6Molitch ME. Prolactin in human reproduction[M]//Strauss JF, Barbieri RL. Yen and Jaffe' s reproductive endocrinology: physiology, pathophysiology and clinical management. 5th ed. Philadelphia: Elsevier Saunders, 2004:93-123.
  • 7Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas[J]. Clin Endocrinol (Oxf), 2006, 65(2):265-273.
  • 8Serri O, Chick CL, Ur E, et al. Diagnosis and management of hyperprolactinemia[J]. CMAJ, 2003, 169(6):575-581.
  • 9Faglia G, Conti A, Muratori M, et al. Dihydroergocriptine in management of mieroprolactinomas[J]. J Clin Endocrinol Metab, 1987, 65(4):779-784.
  • 10Pereira AM. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia[J]. Curt Opin Endocrinol Diabetes Obes,2011,18(4):264-268.DOI: 10.1097/MED.0b013e 328347c94a.

共引文献86

同被引文献12

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部